Marina Sobol, MD
Neurology · Edison, NJNPI 1841344694
Payments from drug & device makers
Across 370 payments — averaging $185.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$49K
- Biohaven Pharmaceuticals, Inc.$13K
- Biohaven Pharmaceutical Holding Company Ltd.$2K
- Teva Pharmaceuticals USA, Inc.$996
- Lilly USA, LLC$810
- Neurocrine Biosciences, Inc.$410
- plus $2K from 28 others
What the payments were for
- Speaking & faculty fees$60,37588%
- Travel & lodging$4501%
- Food & beverage$7,61511%
- Education$1290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 158 | $48,662 |
| Biohaven Pharmaceuticals, Inc. | 17 | $12,925 |
| Biohaven Pharmaceutical Holding Company Ltd. | 13 | $2,424 |
| Teva Pharmaceuticals USA, Inc. | 33 | $996 |
| Lilly USA, LLC | 32 | $810 |
| Neurocrine Biosciences, Inc. | 14 | $410 |
| Novartis | 23 | $317 |
| Lundbeck LLC | 7 | $294 |
| Axsome Therapeutics, Inc. | 4 | $247 |
| Biogen | 14 | $219 |
| AstraZeneca | 7 | $196 |
| Eisai Inc. | 4 | $172 |
| Argenx US, Inc. | 1 | $114 |
| Boston Scientific | 1 | $106 |
| Amgen | 7 | $102 |
| Assertio Therapeutics, Inc. | 7 | $100 |
| UCB, Inc. | 1 | $94 |
| Upsher-smith Laboratories LLC | 3 | $46 |
| Avanir Pharmaceuticals, Inc. | 3 | $44 |
| Pfizer | 2 | $32 |
| GE HealthCare | 2 | $30 |
| Supernus Pharmaceuticals, Inc. | 2 | $27 |
| Amneal Pharmaceuticals LLC | 2 | $26 |
| Adamas Pharmaceuticals, Inc. | 2 | $24 |
| Endo Pharmaceuticals Inc. | 2 | $24 |
| Impel Pharmaceuticals Inc. | 1 | $16 |
| Sanofi | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| Kyowa Kirin, Inc. | 1 | $14 |
| Vertical Pharmaceuticals, LLC | 1 | $12 |
| Almatica Pharma LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$45,470
- NURTEC ODT$14,957
- QULIPTA$7,104
- Austedo XR$491
- KISUNLA$319
- VYEPTI$253
- Symbravo$232
- INGREZZA$226
- AJOVY$123
- Leqembi$122
- BOTOX$116
- VYVGART HYTRULO$114
- SOLIRIS$112
- GENERAL DBS$106
- VRAYLAR$102
How this compares
$68,569 in reported general payments places this provider in the 85th percentile of 521 neurology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 42 | $67,136 |
| QuliptaAtogepant | 28 | $29,242 |
| BotoxOnabotulinumtoxina | 21 | $27,262 |
| Aimovig AutoinjectorErenumab-Aooe | 26 | $24,365 |
| Emgality PenGalcanezumab-Gnlm | 28 | $22,992 |
| Nurtec OdtRimegepant Sulfate | 11 | $22,880 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 18 | $13,628 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 11 | $6,813 |
| Gabapentin | 121 | $3,781 |
| Memantine Hcl ErMemantine Hcl | 18 | $3,289 |
| Memantine Hcl | 61 | $1,524 |
| Tizanidine Hcl | 38 | $1,090 |
| RizatriptanRizatriptan Benzoate | 19 | $950 |
| Duloxetine Hcl | 53 | $819 |
| Amitriptyline Hcl | 72 | $802 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta, Botox | $48,662 | $123,64191 claims |
| PfizerNurtec Odt | $32 | $22,88011 claims |
| Upsher-smith Laboratories LLCTopiramate | $46 | $64238 claims |
| Almatica Pharma LLCSertraline Hcl | $12 | $35619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 521 neurology providers in New Jersey.
Other neurology in Edison
- Sue MingEdison$247K
- Jawad KirmaniEdison$130K
- Diosely SilveiraEdison$113K
- Igor SobolEdison$103K
- Siddharth KapoorEdison$87K
- Wei Wei MaEdison$85K
- Joseph LandolfiEdison$82K
- Mary Ann PiconeTeaneck$2.8M
- Steven BromleyAudubon$1.7M
- David DuncanNeptune$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.